潰瘍性大腸炎：グローバル医薬品市場動向（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 29
3.2 Symptoms 30
3.2.1 Quality of Life 31
4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 33
4.2.1 Being Caucasian and Jewish can increase the risk of UC by almost 37 times 34
4.2.2 A family history of UC in first-degree relatives can increase the risk of the disease by almost three-fold 34
4.2.3 Current smokers have a lower risk of developing UC than former smokers or never smokers 35
4.3 Global Trends 36
4.3.1 US 37
4.3.2 5EU 39
4.3.3 Japan 42
4.3.4 Canada 44
4.3.5 China 45
4.3.6 India 47
4.4 Forecast Methodology 48
4.4.1 Sources Used 50
4.4.2 Sources Not Used 56
4.4.3 Forecast Assumptions and Methods 57
4.5 Epidemiological Forecast of UC (2012-2022) 63
4.5.1 Incident Cases of UC 63
4.5.2 Age-Specific Incident Cases of UC 65
4.5.3 Sex-Specific Incident Cases of UC 66
4.5.4 Age-Standardized Incidence Rates 69
4.6 Epidemiological Forecast for UC Prevalent Cases (2012-2022) 70
4.6.1 Prevalent Cases of UC 70
4.6.2 Age-Specific Prevalent Cases of UC 72
4.6.3 Sex-Specific Prevalent Cases of UC 74
4.6.4 Age-Standardized Prevalence Rate of UC in All Markets 76
4.7 Discussion 77
4.7.1 Epidemiological Forecast Insight 77
4.7.2 Limitations of the Analysis 78
4.7.3 Strengths of the Analysis 79
5 Disease Management 80
5.1 Diagnosis and Treatment Overview 80
5.1.1 Diagnosis 80
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 84
5.1.3 Clinical Practice 85
5.2 US 89
5.3 France 92
5.4 Germany 94
5.5 Italy 96
5.6 Spain 98
5.7 UK 100
5.8 Japan 102
5.9 Canada 104
5.10 China 106
5.11 India 108
6 Competitive Assessment 110
6.1 Overview 110
6.2 Strategic Competitor Assessment 111
6.3 Product Profiles – Major Brands 113
6.3.1 Remicade (infliximab) 113
6.3.2 Humira (adalimumab) 121
6.3.3 Simponi (golimumab) 127
6.3.4 Apriso (mesalamine) 131
6.3.5 Asacol HD (mesalamine) 137
6.3.6 Lialda (mesalamine) 142
6.3.7 Pentasa (mesalamine) 146
6.3.8 Colazal (balsazide disodium) 150
6.3.9 Giazo (balsalazide disodium) 154
6.3.10 sfRowasa (mesalamine) 158
6.3.11 Uceris (budesonide) 161
6.3.12 Other Drug Classes Used in the Treatment of UC 165
6.4 Biosimilars 166
6.4.1 Introduction 166
6.4.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases 167
6.4.3 Biosimilars in the Immunology Community 167
6.4.4 By the Numbers: Biosimilars in Development 168
6.4.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 170
6.4.6 Biosimilars’ Forecast 171
7 Opportunity and Unmet Need 173
7.1 Overview 173
7.2 Unmet Needs 174
7.2.1 Curative Therapy for Severe UC Patients 174
7.2.2 Diagnostic Markers for Disease Severity 174
7.2.3 Personalized Therapy 175
7.2.4 A Replacement for Steroids 175
7.2.5 Novel Oral Drug Formulations 176
7.2.6 Preventative Medicine for Lowering the Associated Colorectal Cancer Risk 177
7.2.7 Improved Management of Infectious Adverse Events 177
7.3 Unmet Needs Gap Analysis 178
7.4 Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools 179
7.5 Predictors of Medically-Refractory Disease 180
8 Pipeline Assessment 181
8.1 Overview 181
8.2 Clinical Trial Mapping 181
8.2.1 Clinical Trials by Country 181
8.3 Clinical Trials by Phase and Trial Status 182
8.4 Promising Drugs in Clinical Development 183
8.4.1 Entyvio (vedolizumab) 185
8.4.2 Xeljanz (tofacitinib) 195
8.4.3 Kappaproct (DIMS 0150) 202
9 Current and Future Players 208
9.1 Overview 208
9.2 Trends in Corporate Strategy 211
9.3 Company Profiles 212
9.3.1 Johnson & Johnson 212
9.3.2 AbbVie 214
9.3.3 Takeda Pharmaceuticals 216
9.3.4 Warner Chilcott 218
9.3.5 Salix Pharmaceuticals/Santarus 220
9.3.6 Shire Pharmaceuticals 222
9.3.7 Ferring Pharmaceuticals 224
9.3.8 Pfizer 225
9.3.9 InDeX Pharmaceuticals 227
10 Market Outlook 230
10.1 Global Markets 230
10.1.1 Forecast 230
10.1.2 Drivers and Barriers – Global Issues 235
10.2 United States 239
10.2.1 Forecast 239
10.2.2 Key Events 243
10.2.3 Drivers and Barriers 243
10.3 France 246
10.3.1 Forecast 246
10.3.2 Key Events 250
10.3.3 Drivers and Barriers 250
10.4 Germany 253
10.4.1 Forecast 253
10.4.2 Key Events 257
10.4.3 Drivers and Barriers 257
10.5 Italy 259
10.5.1 Forecast 259
10.5.2 Key Events 263
10.5.3 Drivers and Barriers 263
10.6 Spain 265
10.6.1 Forecast 265
10.6.2 Key Events 269
10.6.3 Drivers and Barriers 269
10.7 United Kingdom 271
10.7.1 Forecast 271
10.7.2 Key Events 275
10.7.3 Drivers and Barriers 275
10.8 Japan 277
10.8.1 Forecast 277
10.8.2 Key Events 281
10.8.3 Drivers and Barriers 281
10.9 Canada 284
10.9.1 Forecast 284
10.9.2 Key Events 287
10.9.3 Drivers and Barriers 287
10.10 China 289
10.10.1 Forecast 289
10.10.2 Key Events 291
10.10.3 Drivers and Barriers 292
10.11 India 294
10.11.1 Forecast 294
10.11.2 Key Events 296
10.11.3 Drivers and Barriers 297
11 Appendix 300
11.1 Bibliography 300
11.2 Abbreviations 311
11.3 Methodology 316
11.4 Forecasting Methodology 316
11.4.1 Diagnosed UC Patients 316
11.4.2 Percent Drug-Treated Patients 317
11.4.3 Drugs Included in Each Therapeutic Class 317
11.4.4 Launch and Patent Expiry Dates 317
11.4.5 General Pricing Assumptions 318
11.4.6 Individual Drug Assumptions 319
11.4.7 Generic Erosion 321
11.4.8 Pricing of Pipeline Agents 321
11.5 Physicians and Specialists Included in This Study 322
11.6 Primary Research – Prescriber Survey 324
11.7 About the Authors 325
11.7.1 Author 325
11.7.2 Epidemiologist 326
11.7.3 Global Head of Healthcare 326
11.8 About GlobalData 327
11.9 Disclaimer 327